Member Posts > Cardiol Therapeutics to Showcase Cardiovascular Breakthroughs at TD Cowen Conference
Cardiol Therapeutics Inc., a biotechnology company specializing in the development of anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases, has confirmed its participation in the TD Cowen 45th Annual Health Care Conference. The company will present in Boston on March 5, 2025, at 11:10 AM EST, offering insights into its cutting-edge research and clinical advancements.
This announcement is part of Cardiol Therapeutics' broader strategy to engage with key stakeholders in the medical and investment communities. On February 11, 2025, the company presented at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, sharing updates on its clinical pipeline targeting inflammatory heart conditions. Similarly, on September 26, 2023, CEO David Elsley provided an extensive overview of the company's therapeutic programs at the Cantor Fitzgerald 2023 Global Healthcare Conference.
By continuously presenting at leading industry events, Cardiol Therapeutics is solidifying its position at the forefront of cardiovascular therapy development, fostering collaborations and investment opportunities that drive its mission forward.

#CardiolTherapeutics #HeartDiseaseResearch #MedicalBreakthroughs #HealthcareInvestments #PharmaUpdates #BiotechInnovation